[pubmed] Age at sampling and sex distribution of AChRAb vs. MuSKAb myasthenia gravis in a large Greek population

[RSS-Bot]

Clin Neurol Neurosurg. 2021 Jul 27;208:106847. doi: 10.1016/j.clineuro.2021.106847. Online ahead of print.

ABSTRACT

OBJECTIVE: Myasthenia gravis (MG) is a typical B-cell-mediated neuromuscular junction disease that can be classified into seropositive and seronegative subtypes. Association of patients' age at sampling and sex with the two major seropositive MG subcategories, i.e., MGs linked to antibodies directed against the acetylcholine receptor (AChRAb) and against the muscle-specific kinase (MuSKAb), has not been compared in a large population.

METHODS: We performed a retrospective analysis of samples from patients with MG in Greece who underwent neurochemical diagnostic evaluation between January 2, 2013, and August 31, 2016.

RESULTS: Overall, 1620 adult (623 male and 997 female patients; male-to-female ratio = 0.62) and 51 pediatric patients were found to be seropositive for MG. The distributions in both male and female patients were bimodal in the total and AChRAb MG cases but not in the total MuSKAb MG cases. Significant differences in the age at sampling distribution between the male and female adult patients were observed only in the AChRAb MG subtype. Significant differences between the AChRAb and MuSKAb MG categories were noted in the mean age values (60.10 and 51.49 years, respectively, for female and 65.69 and 56.19 years, respectively, for male adult patients).

CONCLUSION: Our findings confirm an uneven profile of age at sampling and sex between the AChRAb and MuSKAb MG cases in a large population. Future mechanistic studies can elucidate the cause of these differences. Moreover, clinical studies can explore how such differences can affect MG treatment and prognosis.

PMID:34343914 | DOI:10.1016/j.clineuro.2021.106847


Source: https://pubmed.ncbi.nlm.nih.gov/3434391 ... 1&v=2.14.5